Strategy to Overcome Opioid Related Gastrointestinal Adverse Effects

References

1. Goudas LC, Bloch R, Gialeli-Goudas M, Lau J, Carr DB. The epidemiology of cancer pain.Cancer Invest. 2005;23:182-190.
2. Burton AW, Fanciullo GJ, Beasley RD, Fisch NJ. Chronic pain in the cancer survivor: a new frontier. Pain Med 2007;8:189-198.
3. European Association for Palliative Care: Morphine in cancer pain: Modes of administration - Expert Working Group of the European Association for Palliative Care. BMJ 1996;312:823-826.
4. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-2554.
5. Swegle JM, Logemann C Management of common opioidinduced adverse effects. Am Fam Physician 2006;74:1347-1354.
6. McNicol E, Horowicz-Mehler N, FiskRA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-256.
7. Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 1998;38:74-818.
8. McDonald P, Graham P, Clayton M, et al. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med 1991;5:323-329.
9. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained release oral morphine in cancer pain: Preference, efficacy, and quality of life?The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997;13:254-261.
10. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16:1588-1593.
11. Neal EA, Meffin PJ, Gregory PB, et al. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 1979;77:96-102.
12. Crotty B, Watson EJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989;36:501-506.
13. Qierny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542-2554.
14. Babul N, Provencher L, Laberge F, et al. Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain. J Clin Pharmacol 1998;38:74-81.
15. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-857.
16. Qierny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995;76:1283-1293.
17. McDonald P, Graham P, Clayton M, et al. Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med 1991;5:323-329.
18. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989;36:169-176.
19. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995;80:290-295.
20. Wiersema MJ, Wiersema LM. Endosonography-guided celiac plexusneurolysis. Gastrointest Endosc 1996;44:656-662.
21. Gunaratnam NT, Sarma AV, Norton ID et al. A prospective study of EUSguided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001;54:316-324.
22. Doi S, Yasuda I, Kawakami H, et al. Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial. Endoscopy. 2013;45:362-369.
23. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182:11S-18S.
24. De Schepper HU, Gemonini F, Park MI, CamilleriM. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-394.
25. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16(suppl 2):17-28.
26. Shook JE, Pelton JT, Hruby VJ, Buries TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther 1987;243:492-500.
27. Hunt R, Fazekas B, Thome D, Brooksbank M. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage. 1999;18:111-119.
28. Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84:105-109.
29. De Schepper НЦ Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004;16:383-394.
30. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64.
31. Simpson K, Leyendecker P, Hopp M, et al. Fixed ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;24:3503-3512.
32. Clemens KE, Mikus G. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother 2010;11:297-310.
33. Yuan CS, Wei G, Foss JF, O5Connor M, Karrison T, Osinski J. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002;300:118-123.
34. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358:2332-2343.